Canertinib (CI-1033, PD-183805) for cell activation

Canertinib is an irreversible tyrosine kinase inhibitor. It not only inhibits tyrosine phosphorylation but also enhances ubiquitinylation and accelerates endocytosis and subsequent intracellular destruction of ErbB-2 molecules.  Canertinib alkylates a cysteine residue specific to ErbB receptors.  The degradative pathway of ErbB receptor tyrosine kinases stimulated by tyrosine kinase inhibitors appears to be chaperone mediated, and thus is similar to the pathways activated by the heat shock protein 90 (Hsp90) antagonist geldanamycin and by stress-induced mechanisms. 

N/A

289499-45-2

558.86

Biochemicals

CI-1033, PD-183805, PD 183806

C₂₄H₂₅ClFN₅O₃ . 2HCl

Off-white to pale green solid

N/A

No

Yes

≥99%

DMSO (100 mg/ml)

-20°C

RT

24months

Protect from air and moisture

cell

For cells, cell lines and tissues in culture till half confluency.